A Phase 4 interventional study of Dotarem®-enhanced MRI and non-enhanced MRI in Renal Insufficiency, sponsored by Guerbet. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-09.
Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Renal Insufficiency with a site in France — 13 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · France.
Among the 107 studies in Renal Insufficiency with a site in France, this one is the 30th largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2008, is one of 8 in phase 4, and was the 11th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →13 of the 107 studies in Renal Insufficiency with a site in France are open now. Recruiting first, the newest first:
Takeda · Sites in France, Belgium, Estonia and 4 more countries
Ages 18+
GCS Ramsay Santé pour l'Enseignement et la Recherche · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 6–17 · Men only
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 1994; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 108 across the 67 interventional studies, 186 across the 39 observational. Of the 75 that completed or were terminated, 14 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 107 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 5 studies filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Renal Insufficiency with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07341516Paris Translational Research Center for Organ TransplantationWorldwide Assessment of Deceased Donor Kidney Utilization | 2026-11 |
| NCT05117450CHU de ReimsComparison of HYDROLINK™ and HeprAN™ mEmbranes in a Per Dialytic Heparin Weaning Strategy in Chronic Hemodialysis Patients | 2026-11-17 |
| NCT07853677University Hospital, Strasbourg, FranceImpact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis | 2026-12-31 |
| NCT04561362BicycleTx LimitedStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | 2027-01 |
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 107 studies in Renal Insufficiency with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine.
Patients with renal insufficiency not requiring hemodialysis and scheduled to undergo a contrast enhanced MRI or unenhanced MRI examination to specify a diagnosis, were selected for inclusion. Two groups of patients were defined on the basis of the planned imaging procedure selected to obtain a diagnosis: those undergoing a Dotarem®-enhanced MRI and those undergoing an unenhanced MRI.
A clinically significant increase in serum creatinine levels after the contrast-enhanced MRI exam was used as an indication of contrast induced nephrotoxicity. A blood test was performed 24h before the MRI in order to evaluate baseline creatinine values. 72h after the exam, a second blood test was performed. An increase in creatinemia above 25% from baseline levels was defined as a contrast-induced nephrotoxic reaction. The primary endpoint of the study assessed the percentage of patients presenting a contrast-induced nephrotoxic reaction in order to show a non inferiority of enhanced as compared to non-enhanced MRI exams.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
Drug: Dotarem®-enhanced MRI
Patients undergoing non-enhanced MRI for diagnostic purposes
Other: non-enhanced MRI
Single IV administration before MRI exam
Also known as: Gadoterate meglumine, Gadoteric acid
non injected MRI
Also known as: unenhanced MRI
Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population.
Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.
Time frame: baseline pre MRI and 3 days post MRI
Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population.
Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.
Time frame: Baseline pre MRI and 3 days post MRI
Percent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population.
Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.
Time frame: Baseline pre MRI and 3 days post MRI
Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population
Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.
Time frame: Baseline pre MRI and 3 days post MRI
Percent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population
eGFR was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.
Time frame: Baseline pre MRI and 3 days post MRI
eGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population
eGFR (estimated Glomerular Filtration Rate) was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.
Time frame: Baseline pre MRI and 3 days post MRI
This study did not use randomization. Eligible patients who provided written consent were enrolled chronologically in each investigational center. A total of 142 patients were screened between 29 January 2008 and 05 May 2011, 135 of whom were included in 15 European centers, eight centers in France, three in Belgium, two in Spain and two in Italy.
| Milestone | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| Started | 75 | 57 |
| Completed | 70 | 44 |
| Not completed | 5 | 13 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Protocol violation | 0 | 13 |
Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.
| Number of patients | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis Set Population. | 1 | 0 |
Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.
| Percentage of change from baseline | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| Percent Change of Serum Creatinine Level From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population. | -1.40 ± 10.36 | -3.48 ± 9.92 |
Comparing the number of patients experiencing an increase of creatinine of at least 25% over baseline levels after Dotarem®-enhanced MRI and after non-enhanced MRI in patients with at least a moderate renal insufficiency.
| Number of patients | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of at Least 25% Over Baseline Levels, in the Per Protocol Population. | 1 | 0 |
Serum creatinine levels were measured at baseline and at 72±24 hours after examination. The percentage of change in creatinemia from baseline was calculated for both the Dotarem® and the non-enhanced groups.
| Percentage of change from baseline | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| Percent Change of Serum Creatinine Level Variation From Baseline to 72±24 Hours After Examination, in the Per Protocol Population | 0.05 ± 10.84 | -5.17 ± 9.16 |
eGFR was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.
| Percentage of change from baseline | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| Percent Change of Estimated Glomerular Filtration Rate (eGFR) Values From Baseline to 72±24 Hours After Examination, in the Full Analysis Set Population | 3.02 ± 12.51 | 5.55 ± 12.94 |
eGFR (estimated Glomerular Filtration Rate) was assessed using creatinemia and the Modification of Diet in Renal Disease (MDRD) study equation. eGFR were evaluated in terms of mean difference between the pre- and post-MRI procedure. The eGFR variation was expressed as a percentage of change from baseline values.
| Percentage of change from baseline | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| eGFR Values Variation Between Baseline and 72±24 Hours After Examination, in the Per Protocol Population | 1.37 ± 12.65 | 7.58 ± 12.82 |
Collected over The period of observation for Adverse Events (AEs) collection extended from the time of patient informed consent until the end of his/her follow-up (i.e. 72 ±24hrs or 14 days after the imaging procedure) or until patient early withdrawal from the trial.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem®-Enhanced MRI | — | 0/70 (0%) | 6/70 (8.6%) |
| Non-enhanced MRI | — | 0/44 (0%) | 0/44 (0%) |
| Event | Dotarem®-Enhanced MRI | Non-enhanced MRI |
|---|---|---|
| HematomaVascular disorders | 1/70 | 0/44 |
| Abdominal pain upperGastrointestinal disorders | 1/70 | 0/44 |
| HypotensionVascular disorders | 1/70 | 0/44 |
| Blood creatinin increasedInvestigations | 1/70 | 0/44 |
| toothacheGastrointestinal disorders | 1/70 | 0/44 |
| ConstipationGastrointestinal disorders | 1/70 | 0/44 |
| Age, Continuous(years) | Dotarem®-Enhanced MRI | Non-enhanced MRI | Total |
|---|---|---|---|
| Mean | 69.6 ± 11.5 | 66.2 ± 12.2 | 67.9 ± 12.0 |
| Age, Categorical(Participants) | Dotarem®-Enhanced MRI | Non-enhanced MRI | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 20 | 44 |
| >=65 years | 51 | 37 | 88 |
| Sex: Female, Male(Participants) | Dotarem®-Enhanced MRI | Non-enhanced MRI | Total |
|---|---|---|---|
| Female | 24 | 23 | 47 |
| Male | 51 | 34 | 85 |
| Region of Enrollment(participants) | Dotarem®-Enhanced MRI | Non-enhanced MRI | Total |
|---|---|---|---|
| France | 44 | 11 | 55 |
| Belgium | 14 | 7 | 21 |
| Spain | 17 | 23 | 40 |
| Italy | 0 | 16 | 16 |
The record gives a start of Jan 2008, a primary completion of May 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine